Dr. Susan Perlman, MD
Claim this profileUniversity of California - Los Angeles
Affiliated Hospitals
University Of California, Los Angeles
UCLA Ataxia Center
Clinical Trials Susan Perlman, MD is currently running
Natural History Study
for Friedreich Ataxia
This project is a global, multicenter, prospective, longitudinal, observational natural history study that can be used to understand the disease progression and support the development of safe and effective drugs and biological products for Friedreich ataxia.
Recruiting
1 award
N/A
6 criteria
Omaveloxolone
for Friedreich's Ataxia
In this study, researchers will learn more about the safety of BIIB141, also known as omaveloxolone or SKYCLARYS®. This is a drug available for doctors to prescribe for people with Friedreich's Ataxia, also known as FA. This is known as an "observational" study, which collects health information about study participants without changing their medical care. Participants for this study will be found using a group called the Friedreich's Ataxia Global Clinical Consortium (FA GCC) UNIFIED Natural History Study (UNIFAI). The FA-GCC is a group of study research centers that helps provide clinical care for FA patients and also helps researchers learn more about how FA affects patients over a long time. The main objective of this study is to collect safety information in participants with FA from UNIFAI. Some of the participants in this study will be prescribed BIIB141 for the first time by their own doctors. Some of the participants will have started taking BIIB141 after joining UNIFAI, but less than 12 months before joining this study. The main questions researchers want to answer in this study are: * How many participants had serious adverse events (SAEs)? An adverse event is considered serious when it results in death, is life-threatening, causes lasting problems, or requires hospital care. * How many participants had adverse events (AEs) related to heart failure or liver damage caused by the drug? Researchers will also learn more about : • Why and when participants stopped treatment, left the study, or took more of the drug than was prescribed This study will be done as follows: * Participants will be screened to check if they can join the study. * After joining the study, the participants who had never started BIIB141 treatment before must start it within 6 months. Otherwise, all participants will take BIIB141 throughout this study as prescribed by their own doctor. * During the study, each participant's doctor will decide how often the participant visits the study research center to check on their health. This will be based on the doctor's own clinical judgment and what is recommended by the drug's label. * Data from the participants' regular visits to their doctor will be collected at 1 month, 2 months, 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months. * Each participant will be in the study for up to 5 years.
Recruiting
1 award
N/A
10 criteria
More about Susan Perlman, MD
Clinical Trial Related
5 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Susan Perlman, MD has experience with
- Placebo
- Observational Study
- BIIB132
- TAK-341
- ONO-2808
- Omaveloxolone
Breakdown of trials Susan Perlman, MD has run
Friedreich Ataxia
Spinocerebellar Ataxias
Machado-Joseph disease
Huntington's Disease
Multi-System Atrophy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Susan Perlman, MD specialize in?
Susan Perlman, MD focuses on Friedreich Ataxia and Spinocerebellar Ataxias. In particular, much of their work with Friedreich Ataxia has involved treating patients, or patients who are undergoing treatment.
Is Susan Perlman, MD currently recruiting for clinical trials?
Yes, Susan Perlman, MD is currently recruiting for 3 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Susan Perlman, MD has studied deeply?
Yes, Susan Perlman, MD has studied treatments such as Placebo, Observational Study, BIIB132.
What is the best way to schedule an appointment with Susan Perlman, MD?
Apply for one of the trials that Susan Perlman, MD is conducting.
What is the office address of Susan Perlman, MD?
The office of Susan Perlman, MD is located at: University of California - Los Angeles, Los Angeles, California 90095 United States. This is the address for their practice at the University of California - Los Angeles.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.